<DOC>
	<DOCNO>NCT03025698</DOCNO>
	<brief_summary>This phase II , open label , multi-center , intra-patient dose escalation study characterize pharmacokinetics oral administration eltrombopag combination immunosuppressive therapy pediatric patient previously untreated relapsed/refractory severe aplastic anemia recurrent aplastic anemia . All patient treat eltrombopag 26-week Treatment Period , follow 52-week Follow-Up Period . Patients previously untreated immunosuppressive therapy treat accord standard care , hATG/cyclosporine , addition eltrombopag . Patients relapsed/refractory SAA recurrent AA enrol one two treatment option : hATG/cyclosporine plus eltrombopag cyclosporine plus eltrombopag , depend prior treatment immunosuppressive therapy . After initiate treatment eltrombopag , patient dose assess modified tolerate , target platelet count maximum dose achieve . Pharmacokinetic assessment perform time point intend capture steady state PK start dose high dose achieve . Upon completion Treatment Follow-Up Periods , patient offer opportunity enroll additional 3 year Long Term Follow-Up Period .</brief_summary>
	<brief_title>A Phase II Dose-escalation Study Characterizing PK Eltrombopag Pediatric Patients With Previously Untreated Relapsed Severe Aplastic Anemia Recurrent Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>1 . Age 1 &lt; 18 year 2 . Diagnosis aplastic anemia 3 . Hematopoietic stem cell transplantation ( HSCT ) available suitable treatment option refuse patient . 4 . Bone marrow aspirate/biopsy time 4 week prior first dose eltrombopag 5 . Normal karyotype FISH chromosome 7 8 6 . Performance status score : Karnofsky ≥50 Lansky ≥50 ( depend age ) 8 . Written inform consent sign parent legal guardian prior initiation study specific procedure . Inclusion Criteria specific patient relapsed/refractory SAA recurrent AA : 1 . Prior history diagnosis SAA 2 . Diagnosis relapsed/refractory SAA recurrent AA time enrollment . 3 . Agree concurrent eltrombopag treatment appropriate , investigatorselected IST either hATG + CsA CsA . Inclusion Criteria specific patient previously untreated SAA : 1 . Patients must previously treat SAA 2 . Patients must agree treatment hATG + CsA concurrent eltrombopag . 1 . Prior and/or active medical history : Fanconi anemia ( via chromosomal breakage test growth arrest flow cytometry ) Other know underlying congenital/inherited marrow failure syndromes Symptomatic Paroxysmal Nocturnal Hemoglobinuria ( PNH ) and/or PNH clone &gt; 50 % PMN RBC time enrollment Any cytogenetic abnormality , include limited chromosome 7 myelodysplasia , bone marrow within 4 week study enrollment Myelodysplastic syndrome ( MDS ) Other know suspected underlying primary immunodeficiency Any malignancy 2 . Active infection respond appropriate therapy 3 . Prior eltrombopag thrombopoietin receptor ( TPOR ) agonist treatment least 2 month lack response . 4 . Any range lab value Creatinine &gt; 2.5 × upper limit normal ( ULN ) , Total bilirubin &gt; 1.5 × ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 × ULN</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Eltrombopag</keyword>
	<keyword>hATG</keyword>
	<keyword>CsA</keyword>
	<keyword>previously untreated relapse severe aplastic anemia</keyword>
	<keyword>recurrent aplastic anemia</keyword>
	<keyword>Severe aplastic anemia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunosuppressive therapy</keyword>
	<keyword>ETB115</keyword>
</DOC>